DAFNA Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

DAFNA Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.1M	Sell	42,595 -19,500	-31%	-$3.35M	1.55%	18
2026 Q1	$10.5M	Sell	62,095 -6,000	-9%	-$1.03M	2.39%	11
2025 Q4	$11.5M	Sell	68,095 -34,405	-34%	-$5.59M	2.67%	9
2025 Q3	$14.8M	Hold	102,500	–	–	3.66%	7
2025 Q2	$13M	Hold	102,500	–	–	3.58%	9
2025 Q1	$13.1M	Hold	102,500	–	–	3.72%	8
2024 Q4	$13.6M	Hold	102,500	–	–	3.44%	9
2024 Q3	$14.9M	Hold	102,500	–	–	3.53%	8
2024 Q2	$14.1M	Hold	102,500	–	–	3.36%	8
2024 Q1	$14.1M	Hold	102,500	–	–	3.2%	9
2023 Q4	$13.9M	Hold	102,500	–	–	3.34%	9
2023 Q3	$12.5M	Hold	102,500	–	–	3.9%	7
2023 Q2	$13M	Hold	102,500	–	–	3.56%	6
2023 Q1	$13.2M	Hold	102,500	–	–	3.97%	6
2022 Q4	$13.5M	Hold	102,500	–	–	3.79%	5
2022 Q3	$12M	Hold	102,500	–	–	3.22%	9
2022 Q2	$12.1M	Hold	102,500	–	–	3.29%	9
2022 Q1	$13.4M	Buy	102,500 +61,600	+151%	+$8.02M	3.48%	6
2021 Q4	$6.24M	Hold	40,900	–	–	1.57%	17
2021 Q3	$6.61M	Hold	40,900	–	–	1.75%	14
2021 Q2	$6.69M	Buy	40,900 +500	+1%	+$77K	1.4%	19
2021 Q1	$6.08M	Sell	40,400 -7,000	-15%	-$1.11M	1.44%	17
2020 Q4	$7.18M	Sell	47,400 -8,500	-15%	-$1.21M	2.14%	10
2020 Q3	$7.57M	Buy	55,900 +1,000	+2%	+$136K	2.46%	10
2020 Q2	$7.5M	Sell	54,900 -18,000	-25%	-$2.29M	2.17%	12
2020 Q1	$7.85M	Buy	72,900 +8,000	+12%	+$921K	3.28%	7
2019 Q4	$7.82M	Hold	64,900	–	–	2.68%	10
2019 Q3	$6.46M	Buy	64,900 +3,500	+6%	+$366K	2.43%	9
2019 Q2	$6.7M	Hold	61,400	–	–	2.52%	9
2019 Q1	$6.87M	Sell	61,400 -3,500	-5%	-$384K	2.96%	9
2018 Q4	$6.26M	Buy	64,900 +38,800	+149%	+$4.12M	3.11%	6
2018 Q3	$3.18M	Hold	26,100	–	–	1.31%	24
2018 Q2	$2.87M	Hold	26,100	–	–	1.34%	22
2018 Q1	$2.79M	Hold	26,100	–	–	1.36%	26
2017 Q4	$2.79M	Hold	26,100	–	–	1.5%	23
2017 Q3	$2.9M	Hold	26,100	–	–	1.8%	16
2017 Q2	$2.7M	Hold	26,100	–	–	1.93%	12
2017 Q1	$2.55M	Hold	26,100	–	–	2.16%	14
2016 Q4	$2.31M	Buy	+26,100	New	+$2.38M	2.03%	18
2016 Q3	–	Sell	-18,000	Closed	-$1.54M	–	88
2016 Q2	$1.54M	Hold	18,000	–	–	1.22%	26
2016 Q1	$1.56M	Buy	+18,000	New	+$1.61M	1.35%	23

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

DAFNA Capital Management's IBB Position: Q2 2026 in Review

DAFNA Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 31% in Q2 2026, selling an estimated $3.35M and leaving 42,595 shares worth $8.1M. The position accounts for 1.55% of the portfolio, ranked #18.

DAFNA Capital Management first reported a position in IBB in Q1 2016 and has held it in 41 quarters since. The position peaked at $14.9M in Q3 2024. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

DAFNA Capital Management held 42,595 shares of iShares Biotechnology ETF worth $8.1M as of Q2 2026.
DAFNA Capital Management sold 19,500 iShares Biotechnology ETF shares in Q2 2026, an estimated $3.35M.
iShares Biotechnology ETF made up 1.55% of DAFNA Capital Management's portfolio in Q2 2026, its #18 holding.
DAFNA Capital Management first reported a position in iShares Biotechnology ETF in Q1 2016 and has held it in 41 quarters since.
DAFNA Capital Management's iShares Biotechnology ETF position peaked at $14.9M in Q3 2024.
954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.